Barclays Lowers Bruker (NASDAQ:BRKR) Price Target to $69.00

Bruker (NASDAQ:BRKR) had its target price cut by stock analysts at Barclays from $75.00 to $69.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. Barclays‘s price objective would suggest a potential upside of 14.07% from the company’s previous close.

Other research analysts have also recently issued reports about the company. TD Cowen dropped their price target on Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a research note on Wednesday, August 7th. The Goldman Sachs Group cut their price target on Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a research note on Tuesday, July 9th. Wells Fargo & Company initiated coverage on Bruker in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 price objective for the company. Wolfe Research downgraded shares of Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Finally, Citigroup reduced their target price on shares of Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday, July 10th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $79.36.

Bruker Stock Performance

NASDAQ:BRKR opened at $60.49 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $9.16 billion, a PE ratio of 25.10, a price-to-earnings-growth ratio of 2.32 and a beta of 1.20. Bruker has a twelve month low of $54.55 and a twelve month high of $94.86. The stock’s 50-day simple moving average is $63.83 and its 200 day simple moving average is $66.47.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The company had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The company’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same period last year, the firm posted $0.74 earnings per share. On average, analysts anticipate that Bruker will post 2.61 EPS for the current fiscal year.

Institutional Trading of Bruker

A number of large investors have recently bought and sold shares of BRKR. Nisa Investment Advisors LLC boosted its position in shares of Bruker by 20.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 165 shares in the last quarter. Securian Asset Management Inc. lifted its stake in Bruker by 2.3% in the second quarter. Securian Asset Management Inc. now owns 7,766 shares of the medical research company’s stock valued at $496,000 after buying an additional 175 shares during the period. Covestor Ltd boosted its holdings in shares of Bruker by 139.1% during the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after buying an additional 210 shares in the last quarter. First Horizon Advisors Inc. grew its position in shares of Bruker by 120.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after buying an additional 218 shares during the period. Finally, Ameritas Investment Partners Inc. increased its stake in shares of Bruker by 0.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 30,911 shares of the medical research company’s stock valued at $1,972,000 after acquiring an additional 235 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.